Otic Pharma, Ltd.

Otic pharma, ltd. email format

Verified email-pattern data for Otic Pharma, Ltd. is currently limited. You can still use the company insights and contact sections below.
Otic Pharma Completes Merger with Tokai Pharmaceuticals Company Renamed Novus Therapeutics, Inc; NASDAQ Ticker "NVUS" IRVINE, Calif., May 10, 2017 /PRNewswire/ -- Otic Pharma, Ltd., a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced the close of the previously announced combination with Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI, through May 10, 2017). In connection with the previously announced transaction, Tokai changed its name to Novus Therapeutics, Inc. and effected a 1-for-9 reverse split of its common stock. The common stock is expected to commence trading on a post-reverse split basis upon the opening of trading on May 11, 2017 on the NASDAQ Capital Market under the symbol "NVUS." Read More: http://www.prnewswire.com/news-releases/otic-pharma-completes-merger-with-tokai-pharmaceuticals-300454911.html Novus Therapeutics, Inc. Investor Relations Tel: (949) 238-8090 investors@novustherapeutics.com

Company Details

Founded
-
Address
19900 Macarthur Blvd., Suite 550, Irvine,california 92612,united States
Phone
(949)238-8090
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
HQ
Irvine, California
Looking for a particular Otic Pharma, Ltd. employee's phone or email?

Otic Pharma, Ltd. Questions

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant